<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504205</url>
  </required_header>
  <id_info>
    <org_study_id>SUPERGEN-SGI-0470-01</org_study_id>
    <secondary_id>CDR0000556524</secondary_id>
    <secondary_id>VPCCS-SGI-0470-01</secondary_id>
    <nct_id>NCT00504205</nct_id>
  </id_info>
  <brief_title>MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma</brief_title>
  <official_title>Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed&#xD;
      for cell growth.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating&#xD;
      patients with unresectable or metastatic refractory solid tumor, Hodgkin's lymphoma, or&#xD;
      non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Estimate the maximum tolerated dose (MTD) and define the safety profile of multitargeted&#xD;
           receptor tyrosine kinase inhibitor MP470 in humans.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Estimate the therapeutic response rate for patients receiving MP470.&#xD;
&#xD;
        -  Define the human pharmacokinetic (PK) and pharmacodynamic (PD) profiles of MP470&#xD;
           capsules&#xD;
&#xD;
        -  Evaluate PK-PD relationships.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral multitargeted receptor tyrosine kinase inhibitor MP470 until the&#xD;
      maximum tolerated dose is determined.&#xD;
&#xD;
      Pharmacokinetic and pharmacodynamic analyses are carried out to determine changes in&#xD;
      phosphorylation of extracellular signal-regulated kinase (ERK), Rad51 expression, number of&#xD;
      circulating tumor cells (CTCs), and tumor glucose metabolism measured by&#xD;
      2-[18F]fluoro-2-deoxyglucose positron emission tomography (FDG-PET).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn as trial was never activated by SuperGen&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to treatment according to RECIST criteria</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic assessments (e.g., changes in phosphorylation of ERK, Rad51 expression, number of CTCs, and tumor glucose metabolism measured by FDG-PET)</measure>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>multitargeted receptor tyrosine kinase inhibitor MP470</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histological or cytological diagnosis of unresectable or metastatic solid-tumor cancer&#xD;
             that is refractory to standard therapies OR for which no standard therapy exists&#xD;
&#xD;
               -  Patients with refractory lymphoma (Hodgkin or non-Hodgkin) are also permitted to&#xD;
                  participate&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Active CNS metastases (primary brain tumors are permitted)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70%&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  ANC ≥ 1.5 × 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 100 × 10^9/L&#xD;
&#xD;
          -  Total serum bilirubin ≤ 2 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 × ULN (upper limit of normal for the clinical laboratory), but ≤ 5 ×&#xD;
             ULN is acceptable if due to hepatic metastases&#xD;
&#xD;
          -  Serum albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  LVEF ≥ 50% on ECHO&#xD;
&#xD;
          -  No significant abnormalities on the screening ECG (e.g., left bundle branch block, 3rd&#xD;
             degree AV block, acute myocardial infarction or QTc interval &gt; 450 msec)&#xD;
&#xD;
          -  No history of additional risk factors for torsade de pointes (e.g., heart failure,&#xD;
             hypokalemia or family history of Long QT Syndrome)&#xD;
&#xD;
          -  Able to swallow MP470 capsules&#xD;
&#xD;
          -  Capable of fasting for 6 hours&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months following&#xD;
             completion of study treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Life-threatening illness, medical condition, or organ system dysfunction which, in the&#xD;
             investigator's opinion, could compromise the patient's safety, interfere with the&#xD;
             absorption or metabolism of oral MP470, or put the study outcomes at risk&#xD;
&#xD;
          -  Any serious, uncontrolled active infection that requires systemic treatment&#xD;
&#xD;
          -  History of significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, and/or myocardial infarction&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Recuperated from any prior surgical procedures including at least 4 weeks rest since a&#xD;
             major surgery&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient has received any anticancer agent(s) within the past 3 weeks, including&#xD;
             investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin),&#xD;
             immunotherapy, biologic, or hormonal therapy other than luteinizing hormone-releasing&#xD;
             hormone (LHRH) agonists&#xD;
&#xD;
          -  Patient has received radiation therapy within the past 4 weeks&#xD;
&#xD;
          -  Patient has a grade 2 or more severe toxicity (other than alopecia) continuing from&#xD;
             prior anticancer therapy&#xD;
&#xD;
          -  Patient requires treatment with immunosuppressive agents other than corticosteroids&#xD;
             that have been at stable doses for at least 2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Berk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Astex Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-4512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

